Conference Call and Webcast at 8:30 AM Eastern Time
NEW
YORK, Nov. 1, 2023 /PRNewswire/
-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ)
("PAVmed" or the "Company"), a diversified commercial-stage medical
technology company, operating in the medical device, diagnostics,
and digital health sectors, today announced that it will host a
business update conference call and webcast on Wednesday, November 15, 2023, at 8:30 AM EST. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief
Executive Officer, will provide a business update including an
overview of the Company's operations and growth strategy. In
addition, Dennis McGrath,
PAVmed's President and Chief Financial Officer, will discuss the
Company's third-quarter 2023 financial results.
The webcast will be available at the investor
relations section of the Company's website at pavmed.com.
Alternatively, to access the conference call by telephone,
U.S.-based callers should dial 1-833-816-1419 and international
listeners should dial 1-412-317-0512. All listeners should provide
the operator with the conference call name "PAVmed Business Update"
to join.
Following the conclusion of the conference call, a replay will
be available for 30 days on the investor relations section of the
Company's website at pavmed.com.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology
company operating in the medical device, diagnostics, and digital
health sectors. Its majority-owned subsidiary, Lucid
Diagnostics Inc. (Nasdaq: LUCD), is a commercial-stage cancer
prevention medical diagnostics company that markets the
EsoGuard® Esophageal DNA Test and
EsoCheck® Esophageal Cell Collection Device—the
first and only commercially available tools designed with the goal
of preventing cancer and cancer deaths through widespread, early
detection of esophageal precancer in at-risk patients. Its
other majority-owned subsidiary, Veris Health Inc., is a digital
health company focused on enhanced personalized cancer care through
remote patient monitoring using implantable biologic sensors with
wireless communication along with a custom suite of connected
external devices. Veris is concurrently developing an implantable
physiological monitor, designed to be implanted alongside a
chemotherapy port, which will interface with the Veris Cancer Care
Platform.
For more and for more information about PAVmed, please
visit pavmed.com.
For more information about Lucid Diagnostics, please
visit luciddx.com.
For more information about Veris Health, please
visit verishealth.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pavmed-to-hold-a-business-update-conference-call-and-webcast-on-november-15-2023-301974198.html
SOURCE PAVmed Inc.